Not marketing

I have come across several instances (lurasidone being a case in point) where a manufacturer has registered one or more strengths of their entity, without applying for the strength to be marketed. An enquiry with Takeda, which markets Latuda (lurasidone), as to why 18.5 mg is not available in NL remains open.